Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kairos Pharma, Ltd.

0.8670
+0.01401.64%
Post-market: 0.95300.0860+9.92%18:11 EDT
Volume:48.75K
Turnover:42.30K
Market Cap:14.47M
PE:-3.78
High:0.8900
Open:0.8452
Low:0.8400
Close:0.8530
Loading ...

BRIEF-Kairos Pharma Remains Financially Strong Despite Recent Economic Headwinds

Reuters
·
24 Apr

Kairos Pharma Ltd - Remains Financially Strong Despite Recent Economic Headwinds

THOMSON REUTERS
·
24 Apr

Kairos Pharma Ltd. Provides Letter to Stockholders

Business Wire
·
24 Apr

Kairos Pharma files to sell 16.29M shares of common stock for holders

TIPRANKS
·
22 Apr

BRIEF-Kairos Pharma Announces Department Of Defense Grant To Support Its Study Of Lead Compound Env105 To Prevent Drug Resistance In Lung Cancer

Reuters
·
17 Apr

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound Env105 to Prevent Drug Resistance in Lung Cancer

THOMSON REUTERS
·
17 Apr

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
17 Apr

HC Wainwright Initiates Kairos Pharma at Buy With $12 Price Target

MT Newswires Live
·
16 Apr

Kairos Pharma: Promising Oncology Pipeline and Strategic Advancements Drive Buy Rating

TIPRANKS
·
16 Apr

Kairos Pharma: Promising Innovations in Cancer Drug Resistance and Immune Enhancement

TIPRANKS
·
04 Apr

Top Calls on Wall Street: Nvidia, Block, Lyft, Best Buy, RH, Zscaler, Ross Stores and More

The Fly
·
03 Apr

Kairos Pharma Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
03 Apr

Kairos Pharma initiated with a Buy at H.C. Wainwright

TIPRANKS
·
03 Apr

Kairos Pharma, Ltd. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
03 Apr

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
31 Mar

BRIEF-Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Reuters
·
31 Mar

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of Env105 in Metastatic, Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
31 Mar

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Business Wire
·
28 Mar

Kairos Pharma Initiated at Buy by Maxim Group

Dow Jones
·
28 Mar

Kairos Pharma Ltd : Maxim Group Initiates Coverage With Buy Rating; Price Target $4

THOMSON REUTERS
·
27 Mar